bioecon Member area
Technology · Health & biomedicine / Therapeutics & platforms

Antibody-drug conjugates (ADCs)

A monoclonal antibody chemically linked to a highly potent cytotoxic payload, delivering chemotherapy-grade cell killing selectively to antigen-expressing tumor cells — one of oncology's clearest recent commercial successes, and also a field where a Phase 3 win on efficacy can still surface a real mortality signal.

Risk: high Pharma & biologics US · EU · CN Science: why it works →Forums and policy: 7 verified 2026-08-08 · 6 Sources (0 independent)

1 · What it gives

An antibody-drug conjugate pairs a monoclonal antibody that targets a tumor-surface antigen with a highly potent cytotoxic payload, joined by a chemical linker engineered to stay stable in circulation and release the payload only after the antibody carries it inside the target cell. The result is chemotherapy-grade cell killing delivered with antibody-level selectivity, and it has become one of oncology’s clearest recent commercial successes: Daiichi Sankyo and AstraZeneca’s Enhertu (trastuzumab deruxtecan) has expanded from HER2-positive breast cancer to a tumor-agnostic EU approval for any HER2-positive solid tumor. But the field’s core engineering trade-off — payload potency versus off-target toxicity — remains unresolved even in late-stage, efficacy-positive trials: ADC Therapeutics’ Phase 3 LOTIS-5 trial of Zynlonta plus rituximab hit its progression-free-survival endpoint in 2026 while showing roughly three times the treatment-emergent death rate of the control arm, concentrated in patients over 75.

The key directions are:

  1. HER2-targeted ADCs: The field’s most commercially mature target, led by Enhertu and RemeGen/Seagen’s disitamab vedotin, expanding from breast and gastric cancer into a widening set of HER2-expressing solid tumors.
  2. Novel payload chemistry: Topoisomerase-I inhibitor payloads (deruxtecan-class) delivering a strong “bystander effect” that kills neighboring antigen-low tumor cells, distinct from the older auristatin/maytansine payload classes.
  3. Linker engineering: Cleavable linkers (protease- or pH-sensitive) that release the payload inside the target cell versus non-cleavable linkers designed for maximum circulating stability.
  4. Combination regimens: Pairing an ADC with a checkpoint inhibitor or a bispecific antibody to raise response rates, which is also where some of the field’s sharpest safety trade-offs are surfacing.

Sectoral value chain#

[Antigen target validation] ──> [Antibody + linker-payload engineering] ──> [Conjugation & GMP manufacturing] ──> [Purification & DAR QC]
                                  │
                          (Clinical trials in target-expressing tumors)
                                  │
                                  ▼
[Combination-regimen development] <─── [Regulatory approval] <─────┘

Value chain levels#

LevelDescriptionKey inputs/outputs
Target validationConfirming the tumor-surface antigen is expressed widely enough, and differentially enough from healthy tissue, to be a viable ADC target.In: Tumor biopsy/expression data.
Out: Validated antigen target.
Antibody + linker-payload engineeringSelecting or engineering the targeting antibody, the cytotoxic payload, and the linker chemistry joining them.In: Target antigen, payload library.
Out: ADC candidate design.
Conjugation & GMP manufacturingChemically attaching payload to antibody at a controlled drug-to-antibody ratio (DAR) under GMP.In: Antibody, linker-payload.
Out: Conjugated drug substance.
Purification & DAR QCChromatographic purification and analytical confirmation of DAR distribution and free-payload levels.In: Crude conjugate.
Out: Release-tested drug substance.
Clinical trialsTrials in antigen-expressing tumor populations, increasingly including combination arms with checkpoint inhibitors or bispecifics.In: Drug product.
Out: Efficacy/safety data.
Regulatory approval & combination developmentApproval, often followed rapidly by label expansion into new tumor types and combination regimens.In: Trial data.
Out: Marketing authorization, expanded indications.

Cross-cutting technologies of the sector:

  • Bystander effect payloads: Membrane-permeable payloads (deruxtecan-class) that diffuse out of the targeted cell after release and kill neighboring tumor cells with lower antigen expression, widening the population an ADC can treat.
  • Site-specific conjugation: Engineering defined attachment points on the antibody (rather than conjugating to random lysines) to produce a homogeneous drug-to-antibody ratio, improving both potency consistency and manufacturability.
  • Cleavable vs. non-cleavable linker chemistry: The choice directly trades off payload release efficiency against circulating stability, and is a large part of why two ADCs against the same target can have very different toxicity profiles.

2 · What it replaces 0 · matched by industry

No graded substitution linked yet.

3 · How to implement 6 steps

  1. 1
    Antibody production
    The targeting monoclonal antibody is expressed in mammalian cell culture (typically CHO cells) and purified to the standard required for subsequent chemical conjugation.
  2. 2
    Linker-payload synthesisSynthesis & conversion
    The cytotoxic payload (a topoisomerase-I inhibitor, auristatin, or maytansinoid, depending on the ADC) is chemically pre-attached to its linker molecule in a separate synthesis stream.
    Who can do this step matched automatically
    China Everbright Environment Group China
    163,050 tonnes
    “Uniquely equipped with the credentials for the R&D, design, and production of both high-efficiency dust filtration materials and SCR denitration catalysts, as well as for the …”
    Rossari Biotech (NSE) India
    industrial scale
    “A liver protectant comprising a combination of Liver extracts, Choline chloride, Inositol, Vitamin B12, Protein Hydrolysate, Biotin, Selenium, Vitamin E and Methylsulfonylmethane.”
  3. 3
    Conjugation reaction
    The linker-payload construct is chemically attached to the antibody, either at engineered site-specific positions or at native reactive residues, under controlled reaction conditions targeting the desired drug-to-antibody ratio.
  4. 4
    Purification and DAR QCPurification & downstreamTesting & analytics
    Chromatography removes unconjugated antibody, free linker-payload, and aggregates, and analytical methods (hydrophobic-interaction or reversed-phase chromatography, mass spectrometry) confirm the DAR distribution meets specification.
    Who can do this step matched automatically
    HLB Genex (ex-GenoFocus) South Korea
    industrial scale
    “With fungal and bacterial secretion systems, we custom produce the evolved enzyme products in large-scale fermentation and downstream processes.”
    Space F South Korea
    “2026-07-12 [Korea's next drug lab is in orbit - The Korea Herald — Space LiinTech is advancing Korea’s foray into space-based drug research with autonomous microgravity platforms …”
    Esco Aster Singapore
    5,000 L industrial scale
    “Adherent cell culture and downstream processing: commercialized Tide Motion bioreactor platform (MiniTide to TideXcell) with closed automated cell harvesting and single-use …”
    Advanced Enzyme Technologies (NSE) India
    ✓ GMP 500 m3
    “Development of robust, scalable fermentation and downstream processing (production and recovery/yield optimization).”
    Turion Labs Singapore
    “Turion Labs is a Singapore-headquartered biotech innovation platform that provides shared laboratory infrastructure, contract research organization (CRO) services, and regulatory …”
  5. 5
    Formulation and sterile fill-finishFormulation & blendingPackaging & fill-finish
    The purified conjugate is formulated into its final buffer and aseptically filled, since ADCs, like most biologics, cannot be terminally sterilized without degrading the antibody or payload.
    Who can do this step matched automatically
    Pakka (ex-Yash Pakka) India
    1940 MT per annum industrial scale
    “Pakka Limited (located in Ayodhya, India) provides regenerative packaging solutions for food products.”
    SyAqua Group Thailand
    “vannamei genetics (broodstock, nauplii, and post-larvae) built on genomic selection/marker-assisted selection plus quantitative genetics (BLUP), with disease resistance screening …”
    RWDC Industries Singapore
    industrial scale
    “2026-04-02 [A Major Step Forward in the Fight Against Microplastics — RWDC Industries is positioning itself as a leader in sustainable biopolymers, specifically Solon PHA, a fully …”
    Advanced Enzyme Technologies (NSE) India
    ✓ GMP 500 m3
    “This is a satellite blending, mixing and formulation facility, located at Vashind near Shahapur and dedicated to the company’s Animal Nutrition business.”
    Ecoware India
    1,500 tons/
    “Our range of 135+ biodegradable and compostable products includes plates, bowls, cups, trays, takeaway containers and custom food packaging solutions trusted by restaurants, cafés, …”
  6. 6
    Release testing and shipmentTesting & analytics
    Each lot undergoes identity, potency, DAR and sterility release testing before cold-chain shipment, with ongoing pharmacovigilance monitoring for the kind of late-emerging safety signals seen in LOTIS-5.
    Who can do this step matched automatically
    Esco Aster Singapore
    5,000 L industrial scale
    “Esco Aster (Singapore) is a cGMP contract research, development and manufacturing organization (CRDMO/CDMO) and bioinnovation venture accelerator that helps clients and …”
    Turion Labs Singapore
    “Turion Labs is a Singapore-headquartered biotech innovation platform that provides shared laboratory infrastructure, contract research organization (CRO) services, and regulatory …”
    Vaxxinova Norway Norway
    industrial scale
    “Vaxxinova develops, produces and markets a wide range of innovative vaccines and diagnostic services to protect livestock and fish against diseases.”

4 · Who delivers

Matched suppliers (matched automatically)

CHITOSEJapanResearch / RTOactive
Vland Biotech 蔚蓝生物 (SSE 603739)ChinaResearch / RTOactive
Esco AsterSingaporeServices / consultingactive
LoopwormIndiaServices / consultingactive
FermelantaJapanProduceractive
Cell AgriTechMalaysiaResearch / RTOactive
PenséesSouth KoreaProduceractive
EcoWin (Dong-A ST sub)South KoreaResearch / RTOactive
SartoriusGermanyProduceractive

Leading companies and institutes (from the brief)

Company / InstituteCountryKey products / platformsTech featuresStatus 2026
Daiichi Sankyo🇯🇵 JapanEnhertu (trastuzumab deruxtecan)Topoisomerase-I payload, tumor-agnostic EU approvalcommercial
AstraZeneca🇬🇧 UKEnhertu (co-developed); DatrowayCo-commercializes Enhertu with Daiichi Sankyocommercial
Seagen🇺🇸 USAAdcetris; PadcevPfizer subsidiary since Dec 2023 ($43B acquisition)commercial
RemeGen🇨🇳 ChinaDisitamab vedotin (Aidixi / RC48-ADC)China’s first domestic ADC approval (2021); Phase 3 combo positive May 2025commercial
ADC Therapeutics🇨🇭 SwitzerlandZynlonta (loncastuximab tesirine)LOTIS-5 Phase 3 PFS-positive but elevated treatment-emergent mortalityclinical (sBLA planned Q4 2026)
Gilead Sciences🇺🇸 USATrodelvy (sacituzumab govitecan)Trop-2-targeted; via 2020 Immunomedics acquisitioncommercial

5 · Rules & route to market

United States

The United States hosts the field’s dominant commercial platform following 2023’s largest ADC-driven acquisition, alongside a second major ADC franchise built on an entirely different tumor-antigen strategy.

Post-acquisition portfolio consolidation, a second blockbuster franchise#

  • Seagen (a Pfizer company): Pfizer’s $43 billion acquisition of Seagen closed in December 2023, bringing Adcetris (brentuximab vedotin) and Padcev (enfortumab vedotin) plus Seagen’s ADC development platform into Pfizer’s oncology portfolio; Seagen had separately in-licensed ex-Asia rights to RemeGen’s disitamab vedotin in 2021.
  • Gilead Sciences: Trodelvy (sacituzumab govitecan), a Trop-2-targeted ADC, is Gilead’s ADC franchise sitting alongside its (separately tabled) antiviral and Kite Pharma CAR-T businesses — a distinct product line built through Gilead’s 2020 acquisition of Immunomedics.
European Union

Europe anchors one half of the field’s biggest commercial success and, separately, supplies the year’s sharpest cautionary data point on ADC safety.

Enhertu’s label expansion, a real mortality signal in a PFS-positive trial#

  • AstraZeneca: co-develops and co-commercializes Enhertu with Daiichi Sankyo; in 2026 the companies secured EU approval of Enhertu as a tumor-agnostic monotherapy for previously treated HER2-positive solid tumors, and FDA priority review for use after neoadjuvant treatment in HER2-positive early breast cancer.
  • ADC Therapeutics: the Swiss company’s Phase 3 LOTIS-5 trial of Zynlonta (loncastuximab tesirine) plus rituximab met its primary progression-free-survival endpoint in 2026, but treatment-emergent adverse-event deaths ran roughly three times higher than the control arm — 27 deaths, over half infection-related, 16 in patients 75 or older — prompting a protocol amendment adding upfront immune-status screening and prophylaxis to a concurrent trial ahead of a planned Q4 2026 regulatory filing.
  • Regulatory pattern: the EMA’s willingness to grant Enhertu a tumor-agnostic (histology-independent) approval, a first for an ADC in the EU, signals how far regulatory confidence in the modality has grown even as the LOTIS-5 result shows the underlying toxicity risk has not gone away.
China

China moved from ADC licensor to genuine co-developer in this field faster than in most other biologics categories, anchored by the country’s first homegrown approved ADC.

First domestic ADC approval, an active Phase 3 combination programme#

  • RemeGen: disitamab vedotin (marketed in China as Aidixi, known in trials as RC48-ADC) became China’s first domestically developed ADC approved for HER2-overexpressing gastric cancer in 2021; RemeGen out-licensed ex-Asia rights to Seagen for $200 million upfront the same year, and in May 2025 reported that a Phase 3 trial combining disitamab vedotin with the PD-1 inhibitor toripalimab as first-line therapy for HER2-expressing urothelial carcinoma hit both its progression-free-survival and overall-survival endpoints.
  • No second China-headquartered company with an approved or late-stage novel ADC comparable to RemeGen’s was confirmed — the category here is currently a single strong producer rather than a broad domestic field.

6 · Money: tenders & grants

GrantAdvancing bio-printing of living cells for regenerative medicine
European Commission · EU
Sep 22, 2027
341 days

7 · Tech stack & innovations

The stack is dominated by the linker-payload chemistry that determines whether an ADC’s potency translates into a workable therapeutic window or into the kind of safety signal LOTIS-5 surfaced.

  1. Topoisomerase-I Inhibitor Payloads:
    • Deruxtecan-class payloads are membrane-permeable after release, producing a bystander effect that kills neighboring tumor cells with lower target-antigen density — a major reason Enhertu-class ADCs work across a wider range of HER2 expression than earlier-generation ADCs required.
  2. Site-Specific Conjugation Chemistry:
    • Engineered cysteine or unnatural amino acid attachment points produce a defined, homogeneous drug-to-antibody ratio (commonly DAR 4 for deruxtecan-class ADCs), versus the heterogeneous DAR distributions produced by conjugating to native lysine residues.
  3. Cleavable Linker Design:
    • Protease-cleavable (valine-citrulline) and pH-sensitive hydrazone linkers are tuned to stay intact in systemic circulation and release payload specifically inside the acidic, protease-rich lysosomal environment of the target cell after antibody-mediated internalization.

Where this appears 7 sources

Appears in 7 distinct sources across 2 regions, 2023–2027.

  • forum programmes 1
  • policy documents 2
  • reports 4

Regions: China · Global

Distinct sources per year
  1. 2021: 0
  2. 2022: 0
  3. 2023: 1
  4. 2024: 2
  5. 2025: 2
  6. 2026: 1
  7. 2027: 1

Matched themes 5

ADC (Antibody-Drug Conjugates) ADCs Antibody-Drug Conjugates (ADCs) Antibody-Drug Conjugates Development Antibody-drug conjugates

Themes from forum programmes, policy documents and reports are mapped to technologies automatically and then reviewed; counts are distinct sources, not mentions, and are not a ranking. data sources and method → · Trending, not yet covered →

Sources 6 · 0 independent · 6 producer sites

Producers' own sites 6

  1. Seagen producer checked 2026-04-14 · link not kept
  2. Daiichi sankyo producer checked 2026-06-25 · link not kept
  3. Astrazeneca producer checked 2025-12-17 · link not kept
  4. Remegen producer checked 2026-06-25 · link not kept
  5. Adc therapeutics producer checked 2026-06-03 · link not kept
  6. Gilead sciences producer checked 2026-08-08 · link not kept